Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Notice to Readers: Availability of Additional Trivalent
Inactivated Influenza Vaccine for Adults
(Afluria®)
On September 28, 2007, CSL Biotherapies, Inc., (King of Prussia, Pennsylvania) received approval from the Food
and Drug Administration for use of
Afluria®, a trivalent inactivated influenza vaccine (TIV) administered intramuscularly
in persons aged >18 years (1). Afluria can be used for any adult influenza vaccine indication
(2).
The addition of Afluria brings to six (five TIVs and one live, attenuated influenza vaccine) the number of
seasonal influenza vaccines licensed for the U.S. market. CDC
estimates that manufacturers of the six vaccines will supply
a record 132 million doses of influenza vaccine for the
2007--08 influenza season.
Afluria is available in a 0.5 mL preservative-free, single-dose, prefilled syringe and in a 5 mL multidose vial
containing 10 doses. Thimerosal, a mercury derivative, is added as a preservative to the multidose vial; each 0.5 mL dose
contains 24.5 µg of mercury. Additional information is available from the manufacturer's package insert
(3) and CSL Biotherapies, Inc., telephone 888-435-8633.
References
Food and Drug Administration. Additional influenza vaccine approved for upcoming influenza season: approval increases available doses to
record level. Rockville, MD: Food and Drug Administration; 2007. Available at
http://www.fda.gov/bbs/topics/news/2007/new01714.html.
Afluria [package insert]. King of Prussia, PA: CSL Biotherapies, Inc.; 2007. Available at
http://www.afluria.com/pi.pdf.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
